Targacept announces decision by AstraZeneca to advance AZD1446 in Alzheimer’s disease
Thursday, 5 January 2012
Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced that AstraZeneca has informed the company that it plans to progress the development of Targacept’s product candidate AZD1446 as a treatment for Alzheimer’s disease.